LPCN logo

LPCN
Lipocine Inc

14,455
Mkt Cap
$52.19M
Volume
134,788.00
52W High
$12.37
52W Low
$2.52
PE Ratio
-4.29
LPCN Fundamentals
Price
$7.58
Prev Close
$7.15
Open
$7.17
50D MA
$8.72
Beta
0.61
Avg. Volume
100,863.87
EPS (Annual)
-$1.77
P/B
3.22
Rev/Employee
$141,191.21
$28.82
Loading...
Loading...
News
all
press releases
Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Lipocine from a "sell" rating to a "hold" rating in a report on Sunday...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 PR Newswire SALT LAKE CITY, March 10...
PR Newswire·21d ago
News Placeholder
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.51% and -52.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for...
PR Newswire·1mo ago
News Placeholder
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN...
PR Newswire·2mo ago
News Placeholder
Lipocine Inc. (NASDAQ:LPCN) Short Interest Update
Lipocine Inc. (NASDAQ:LPCN - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 157,602 shares...
MarketBeat·2mo ago
News Placeholder
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Lipocine Reports Encouraging Progress Post Second Interim Safety...
PR Newswire·3mo ago
News Placeholder
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone PR Newswire SALT LAKE CITY, Dec. 16, 2025 Second Drug...
PR Newswire·3mo ago
News Placeholder
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in...
PR Newswire·4mo ago
<
1
2
...
>

Latest LPCN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.